Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.59+0.00 (+0.29%)

Close on Nov 11, 2026Market cap $164.37MP/E –Yield –

Humacyte statistics

79 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 18, 2027 (estimated, before the open)
Last ex-dividend date: No dividends
Fundamentals through: Sep 30, 2026
Share price as of: Nov 11, 2026

Valuation ratiosIndustry

Market Cap: $164.37M; $282.97M
Enterprise Value: $99.85M; $154.96M
PS Ratio: 68.60; 3.71
PB Ratio: 9.10; 2.17
P/TBV Ratio: 9.10; 2.39

Enterprise valuationIndustry

EV / Sales: 41.67; 2.65

Share statisticsIndustry

Shares Outstanding: 278M; 58M
Shares Change (YoY): 56.7%; 10.9%
Shares Change (QoQ): 0.00%; 0.51%
Float: 256M; 49M
Shares Held by Insiders: 7.97%; 11.6%
Shares Held by Institutions: 26.4%; 56.4%

Short sellingIndustry

Short Interest: 28M; –
Short Interest Change: -7.20%; -0.76%
Short % of Float: 11.0%; 9.06%
Short % of Shares Outstanding: 10.1%; 6.38%
Days to Cover: 7.19; 5.16

Stock price statisticsIndustry

52-Week High: $1.52; –
52-Week Low: $0.34; –
20-Day Moving Average: $0.45; –
50-Day Moving Average: $0.49; –
200-Day Moving Average: $0.78; –
Average True Range (14): $0.06; –
Price Change (1 Week): 31.5%; -0.50%
Price Change (1 Month): 64.9%; -0.33%
Price Change (3 Months): 7.58%; -17.2%
Price Change (6 Months): -47.6%; -20.1%
Price Change (YTD): -38.4%; -20.1%
Price Change (1 Year): -56.2%; -19.3%
Price Change (3 Years): -74.8%; -23.4%
Price Change (5 Years): -94.3%; -76.4%
Average Volume (10 Days): 6M; –
Average Volume (20 Days): 6M; –
Average Volume (90 Days): 6M; –
Relative Volume: 1.06; 0.73
Relative Strength Index (14): 64.9; 47.6
Volatility (1 Year): 114.6%; 80.2%
Beta (5 Years): 2.06; 1.07

MarginsIndustry

Gross Margin: -475.1%; 53.1%
Operating Margin: -4602.9%; -37.1%
Profit Margin: -3955.1%; -32.3%
EBITDA Margin: -4602.9%; -25.0%
FCF Margin: -3697.0%; -9.55%

Returns on capitalIndustry

Return on Equity (ROE): -1423.6%; -51.3%
Return on Assets (ROA): -87.3%; -40.3%
Return on Capital Employed (ROCE): -109.4%; -37.7%

Financial positionIndustry

Current Ratio: 3.34; 3.30
Quick Ratio: 2.64; 2.37
Interest Coverage: -10.97; -6.27

GrowthIndustry

Revenue Growth (YoY): 52.5%; 7.01%

EfficiencyIndustry

Asset Turnover: 0.02; 0.40
Inventory Turnover: 1.15; 2.68
Revenue Per Employee: $13.02K; $426.63K
Profits Per Employee: -$515.02K; -$680.86K
Employee Count: 184; 75
WACC: 15.2%; 10.1%

Income statement (TTM)Industry

Revenue: $2.40M; $66.56M
Gross Profit: -$11.38M; $111.43M
Operating Income: -$110.29M; -$20.20M
Net Income: -$94.76M; -$21.57M
EBITDA: -$110.29M; -$16.36M
EPS (Diluted): -$0.44; -$0.77

Balance sheetIndustry

Cash & Short-Term Investments: $64.52M; $65.30M
Net Cash (Debt): $64.52M; $16.31M
Net Cash Per Share: $0.23; $0.70
Equity (Book Value): $18.06M; $53.12M
Book Value Per Share: $0.07; $1.49
Tangible Book Value: $18.06M; $26.11M
Working Capital: $57.92M; $77.59M

Cash flow (TTM)Industry

Operating Cash Flow: -$88.26M; -$12.07M
Capital Expenditures: -$318.00K; -$939.00K
Free Cash Flow: -$88.58M; -$18.37M
FCF Per Share: -$0.32; -$0.42

Dividends and yieldsIndustry

Earnings Yield: -57.7%; -19.8%
FCF Yield: -53.9%; -8.81%

Taxes and interestIndustry

Interest Expense: $10.06M; $2.98M
Income Tax: $0; $79.50K

Scores and fair valueIndustry

Altman Z-Score: -10.29; 0.28
Piotroski F-Score: 4; 4

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.

Period	HUMA	S&P 500	Difference	HUMA per year	S&P 500 per year
1 month	+46.0%	-2.4%	+48.4 pts
3 months	-16.7%	-1.2%	−15.5 pts
Year to date	-38.4%	+12.3%	−50.7 pts
1 year	-53.8%	+12.4%	−66.2 pts
3 years	-74.8%	+78.8%	−153.6 pts	-36.9%	+21.4%
5 years	-94.0%	+75.2%	−169.1 pts	-43.0%	+11.9%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

28M HUMA shares were sold short on Oct 30, 2026, down 7.2% from the previous report, or 10.98% of the shares available to trade. At recent volumes it would take 7.2 days to buy them back. Over the last 20 sessions, 55.7% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	28,071,815	-7.2%	3,906,141	7.2
Oct 15, 2026	30,251,083	+2.9%	8,274,362	3.7
Sep 30, 2026	29,399,293	-7.6%	4,024,163	7.3
Sep 15, 2026	31,807,566	+6.7%	4,387,750	7.3
Aug 31, 2026	29,813,381	-6.7%	8,761,921	3.4
Aug 14, 2026	31,939,257	+1.4%	9,500,655	3.4
Jul 31, 2026	31,488,080	-2.5%	4,552,596	6.9
Jul 15, 2026	32,283,805	+2.2%	9,658,029	3.3
Jun 30, 2026	31,597,133	-13.9%	25,184,498	1.3
Jun 15, 2026	36,706,340	-8.6%	8,946,847	4.1
May 29, 2026	40,140,620	-2.5%	6,537,068	6.1
May 15, 2026	41,159,014	-7.9%	7,933,504	5.2